Literature DB >> 19352465

Accomplishments in 2007 in the management of hepatobiliary cancers.

Anthony T C Chan1, Yoji Kishi, Stephen L Chan, Jean-Nicolas Vauthey.   

Abstract

Hepatocellular CarcinomaOverview of the Disease IncidencePrognostic or Predictive FactorsCurrent Therapy Standards SurgeryLocoablative TreatmentSystemic TreatmentAccomplishments and Lack of Accomplishments TherapyMilan Criteria to Select Patients for Liver TransplantBiologic AgentsBiomarkersBasic ScienceWhat Needs To Be DoneFuture Directions Comments on ResearchObstacles to ProgressBiliary Tract CancerOverview of the Disease IncidencePrognostic or Predictive FactorsCurrent Therapy StandardsAccomplishments and Lack of Accomplishments TherapyBiomarkersWhat Needs To Be DoneFuture Directions.

Entities:  

Year:  2008        PMID: 19352465      PMCID: PMC2664906     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN: 1934-7820


  77 in total

1.  Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.

Authors:  W Y Lau; T W Leung; S K Ho; M Chan; D Machin; J Lau; A T Chan; W Yeo; T S Mok; S C Yu; N W Leung; P J Johnson
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

2.  Ultrasonically guided subsegmentectomy.

Authors:  M Makuuchi; H Hasegawa; S Yamazaki
Journal:  Surg Gynecol Obstet       Date:  1985-10

Review 3.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

4.  Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival.

Authors:  Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; John Wong
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

5.  Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.

Authors:  Yong Sang Hong; Jeeyun Lee; Sang Cheol Lee; In Gyu Hwang; Seong-Ho Choi; Jin-Seok Heo; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang
Journal:  Cancer Chemother Pharmacol       Date:  2006-12-02       Impact factor: 3.333

6.  Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.

Authors:  Thomas W T Leung; Amanda M Y Tang; Benny Zee; W Y Lau; Paul B S Lai; K L Leung; Joseph T F Lau; Simon C H Yu; Philip J Johnson
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

7.  Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study.

Authors:  R T Poon; I O Ng; C Lau; L X Zhu; W C Yu; C M Lo; S T Fan; J Wong
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

8.  Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.

Authors:  Jeeyun Lee; Tae-You Kim; Myung Ah Lee; Myung Ju Ahn; Hoon-Kyo Kim; Ho Yeong Lim; Nam Su Lee; Byung Joo Park; Jun Suk Kim
Journal:  Cancer Chemother Pharmacol       Date:  2007-03-16       Impact factor: 3.333

9.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.

Authors:  K Okuda; T Ohtsuki; H Obata; M Tomimatsu; N Okazaki; H Hasegawa; Y Nakajima; K Ohnishi
Journal:  Cancer       Date:  1985-08-15       Impact factor: 6.860

10.  Surgical treatment of cholangiocellular carcinoma.

Authors:  R Pichlmayr; P Lamesch; A Weimann; G Tusch; B Ringe
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  5 in total

Review 1.  Management of hepatocellular carcinoma: beyond sorafenib.

Authors:  Stephen L Chan; Tony Mok; Brigette B Y Ma
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  In-hospital mortality after resection of biliary tract cancer in the United States.

Authors:  James E Carroll; Zachary M Hurwitz; Jessica P Simons; James T McPhee; Sing Chau Ng; Shimul A Shah; Waddah B Al-Refaie; Jennifer F Tseng
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

Review 3.  Quality of life and hepatocellular carcinoma.

Authors:  Shipra Gandhi; Sapna Khubchandani; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2014-08

4.  A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression.

Authors:  Katja Piras-Straub; Khaleda Khairzada; Peri Kocabayoglu; Andreas Paul; Guido Gerken; Kerstin Herzer
Journal:  Cancer Med       Date:  2016-08-31       Impact factor: 4.452

5.  Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.

Authors:  Yuri Cho; Jeong-Hoon Lee; Dong Hyeon Lee; Eun Ju Cho; Su Jong Yu; Nam-Joon Yi; Kwang-Woong Lee; Yoon Jun Kim; Jung-Hwan Yoon; Kyung-Suk Suh
Journal:  Oncotarget       Date:  2017-07-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.